C

Clarity Pharmaceuticals Ltd
ASX:CU6

Watchlist Manager
Clarity Pharmaceuticals Ltd
ASX:CU6
Watchlist
Price: 3.38 AUD 0.6% Market Closed
Market Cap: 1.3B AUD

Relative Value

There is not enough data to reliably calculate the relative value of CU6.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CU6 Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
3
Median 3Y
0
Median 5Y
0
Industry
2.7
Forward
237.1
vs History
vs Industry
Median 3Y
-28.4
Median 5Y
-58.3
Industry
21.5
Forward
-16.1
vs History
vs Industry
Median 3Y
-29.2
Median 5Y
-55.5
Industry
16.7
vs History
vs Industry
Median 3Y
-29.1
Median 5Y
-54.9
Industry
23
vs History
25
vs Industry
11
Median 3Y
11.1
Median 5Y
5.8
Industry
2.3
vs History
vs Industry
3
Median 3Y
0
Median 5Y
0
Industry
2.9
Forward
221.3
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.6
vs History
vs Industry
Median 3Y
-25.2
Median 5Y
-52
Industry
13.2
Forward
-14.3
vs History
vs Industry
Median 3Y
-25.2
Median 5Y
-52
Industry
16.6
Forward
-14.3
vs History
vs Industry
Median 3Y
-26.9
Median 5Y
-52.4
Industry
15.8
vs History
vs Industry
Median 3Y
-26.8
Median 5Y
-51.8
Industry
19
vs History
20
vs Industry
3
Median 3Y
50.2
Median 5Y
35.5
Industry
2

Multiples Across Competitors

CU6 Competitors Multiples
Clarity Pharmaceuticals Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Clarity Pharmaceuticals Ltd
ASX:CU6
1.3B AUD 0 -19.6 -17 -17
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.2 37 39.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
213.8B GBP 5 30.7 108.7 159.1
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.4 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
261.8B USD 4.1 13.8 9.8 11.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.6 13.9 9.7 11.3
IE
Endo International PLC
LSE:0Y5F
212.8B USD 91.8 -72.8 337 845
US
Pfizer Inc
NYSE:PFE
141.6B USD 2.3 14.4 7.4 10.1
P/E Multiple
Earnings Growth PEG
AU
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Average P/E: 24.2
Negative Multiple: -19.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.2
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.7
37%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
3%
4.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -72.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.4
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Average EV/EBITDA: 439.6
Negative Multiple: -17
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.7
10%
10.9
CH
Novartis AG
SIX:NOVN
11.7
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.8
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.7
1%
9.7
IE
E
Endo International PLC
LSE:0Y5F
337
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Average EV/EBIT: 1 882.9
Negative Multiple: -17
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.7
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
159.1
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.6
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
845
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4